web analytics

Monoclonal Antibodies; the BioClonetics; Enzolytics Inc (OTCMKTS: ENZC) Merger

0

Enzolytics Inc (OTCMKTS: ENZC) is making a dynamic run up the charts emerging as a volume leader in small caps and one of the most exciting stories on the exchange that has attracted legions of new shareholders as it continues northbound with power. Microcapdaily has been reporting on ENZC since the day the merger was reported and the stock was sub $0.003. In a recent report on ENZC we noted $0.0217 was the price for confirmation of blue sky’s ahead and the stock is currently making a strong run at.

The rise on ENZC comes as the Company merges with BioClonetics Immunotherapeutics, Inc. a biotech in the final stage of development of a parent monoclonal antibody that is being tested at the California National Primate Research Center, UCDavis for the development of a COVID-19 antibody. In a big move Enzolytics recently expanded its lab to the campus of Texas A&M University at the Institute for Preclinical Studies. The US government has reserved a high-tech bio-manufacturing facility at Texas A&M University for mass production of a COVID-19 vaccine as part of a program implemented by President Donald Trump and Enzolytics move to the University puts them at the center of the action. Enzolytics has funding in place and has the capital to move forward on all fronts.

Enzolytics Inc (OTCMKTS: ENZC) operating out of Plano, Texas is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics, flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today.  Enzolytics currently holds a 49% Interest in Immunotech Laboratories BG-Europe. Immunotech BG-Europe has a license for the development and commercialization of Enzolytics Patented ITV-1 Technology. Immunotech BG-Europe , under the branded ImmunH , utilizing the technology has successfully completed Phase III clinical trials at the Specialized Hospital for Active Treatment of Infectious and Parasite Disease in Sofia, Bulgaria, specific for the treatment of HIV/AIDS. ImmunoTech Laboratories BG-Europe has filed for a mass use permit, Phase IV, in Bulgaria. Enzolytics is seeking a Contract Manufacturing Organization (CMO) in the United States to produce the Immunotherapy Treatment to be used as the validation batch in coordination with the Bulgarian regulatory authority and Immunotech BG-Europe. Additionally, ImmunoTech BG-Europe has informed Enzolytics that they will be seeking to register the ImmunH product as a ImmuneModulator, allowing use as an adjunct in additional applications to regulate or normalize the Immune System.

Microcapdaily first reported on ENZC on September 15 when the stock was still deep in triple zero land and moving up fast after the Company first reported the LOI to merge with BioClonetics. See our first report on Enzolytics here when ENCZ was sub $0.003.

As part of the merger BioClonetics co-founder Charles S. Cotropia is the CEO and leader of the merged Company’s. Mr. Cotropia is a successful corporate lawyer and a well-known intellectual property attorney who served as lead counsel in several landmark patent disputes litigated in Federal Courts and the US Patent and Trademark Office. Prior to co-founding BioCLonetics, Mr. Cotropia served as a partner and senior counsel at Sidley Austin LLP. He has litigated over 200 patents in his career.

The Enzolytics and BioClonetics merger has powerful implications; The BioClonetics Clone 3 recombinant mAbs will be combined with the Enzolytics’ flagship compound ITV-1 which is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has been shown to not be subject to viral resistance and is cost effective. The Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates.

To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ENZC

In a very big move Enzolytics recently expanded its lab to the campus of Texas A&M University at its Institute for Preclinical Studies. This expansion will allow the Company to complete the production of monoclonal antibodies against both the HIV virus and the CoronaVirus and collaborate with the biopharma experts on the campus. The US government has reserved a high-tech bio-manufacturing facility at Texas A&M University for mass production of a COVID-19 vaccine as part of a program implemented by President Donald Trump and Enzolytics move to the University puts them at the center of the action. Texas A&M Universities CIADM was one of three centers developed in the U.S. in response to the H1N1 influenza pandemic by BARDA.

While multi-billion dollar pharmaceutical giants including Eli Lilly antibody may be effective the virus is mutating quickly and will likely escape around it. Just this week Seven countries in Europe are reporting mink-related (because they were first discovered in minks) coronavirus mutations that are much less resistant to antibodies. Therefore, while other pharma companies may produce effective antibodies, there will necessarily be a need for additional monoclonal antibodies to be used in tantum with those initially discovered. Dr. Anthony Fauci, head of NIAID/NIH, has repeatedly clarified (as recently in his keynote address at the AIDS International Conference) that a success in treatment of such viruses can be expected to be found in the use of multiple broadly neutralizing HIV antibodies – meaning several antibodies that neutralize a broad spectrum of a virus in its numerous mutation forms.

It will be imperative that produced antibodies target a conserved and immutable site on the virus – otherwise the antibody (over time) will be rendered ineffective due to mutation – known as “virus escape”. The Company’s anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus – one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The coronavirus has structure correlative to that of the HIV virus.

Because its primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs, and knowing the binding site on the HIV virus to which our antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying corresponding structure (amino acid sequences) on the coronavirus that should be targeted to effectively neutralize the coronavirus. Moreover, the Company has proprietary methodology needed to produce anti-coronavirus monoclonal antibodies targeting such sites. Thus, even these initial Eli Lilly trials demonstrate that additional monoclonal antibodies can be expected to be needed to fully treat COVID-19 patients.

For more on ENZC. Subscribe Right Now!

Currently running northbound with power ENZC is one of the most exciting stories in small caps that has gone parabolic in recent days and is nearing $0.0217 price to beat; a break over and its blue sky’s ahead. Enzolytics made a big move when it expanded its lab to the campus of Texas A&M University at the Institute for Preclinical Studies. The US government has reserved a high-tech bio-manufacturing facility at Texas A&M University for mass production of a COVID-19 vaccine as part of a program implemented by the President and Enzolytics move to the University puts them at the center of the action. Enzolytics has funding in place and has the capital to move forward on all fronts. The Company has some important people behind it who would not be wasting their time here unless they really believed they had something. While multi-billion dollar pharmaceutical giants including Eli Lilly antibody may be effective the virus is mutating quickly and will likely escape around it. Therefore, there will always be the need for effective monoclonal antibodies. Dr. Anthony Fauci, head of NIAID/NIH, has repeatedly clarified (as recently in his keynote address at the AIDS International Conference) that a success in treatment of such viruses can be expected to be found in the use of multiple broadly neutralizing HIV antibodies – meaning several antibodies that neutralize a broad spectrum of a virus in its numerous mutation forms. According to CEO Charles S. Cotropia: “We are actively moving forward in our production and testing of such antibodies.” We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.